Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,258,613
-
Share change
-
-121,345
-
Total reported value
-
$7,847,356
-
Put/Call ratio
-
58%
-
Price per share
-
$6.22
-
Number of holders
-
23
-
Value change
-
-$360,077
-
Number of buys
-
17
-
Number of sells
-
10
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q3 2021
As of 30 Sep 2021,
ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) was held by
23 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,258,613 shares.
The largest 10 holders included
INGALLS & SNYDER LLC, MARSHALL WACE, LLP, CREDIT SUISSE AG/, Ikarian Capital, LLC, CITADEL ADVISORS LLC, BANK OF MONTREAL /CAN/, Federation des caisses Desjardins du Quebec, TWO SIGMA INVESTMENTS, LP, Marshall Wace North America L.P., and GROUP ONE TRADING, L.P..
This page lists
24
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.